Investigating how the CARM1-NFIB axis affects small cell lung cancer
Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10879050
This study is looking at how a specific pathway in small cell lung cancer affects tumor growth, and it hopes to find new treatment options by testing a potential drug that targets this pathway for patients with this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10879050 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the CARM1-NFIB signaling pathway in small cell lung cancer (SCLC). Researchers have identified that CARM1, an arginine methyltransferase, modifies NFIB, a transcription factor that promotes tumor growth and metastasis in SCLC. By using genetically engineered mouse models, the study aims to explore the mechanisms behind this interaction and evaluate the potential of small molecule inhibitors targeting CARM1 as a new treatment option for SCLC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who have limited treatment options.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for small cell lung cancer, improving treatment options for patients.
How similar studies have performed: Other research has shown promise in targeting similar molecular pathways in cancer, suggesting potential for success in this approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAZUR, PAWEL K. — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: MAZUR, PAWEL K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, Cancer Patient, CancerModel, Cancers